Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials
Xiao Li, Yaqiong Song, Jianhua Li · 2026
Read Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials by Xiao Li, Yaqiong Song, Jianhua Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13461945.txt.
Description
Xiao Li, Yaqiong Song, and Jianhua Li pool randomized trials, in a 2026 review, on adding immune checkpoint drugs to chemotherapy with nab-paclitaxel across solid tumors. Checkpoint drugs release immune cell brakes so they can attack cancer. Whether the pairing helps across cancer types was unmeasured. The team searched four databases through the start of 2026 for trials comparing the pair against nab-paclitaxel-based care without immune drugs.
Twenty-four trials with 6,682 patients covered five tumor types: lung, breast, pancreatic, stomach, and throat. The pairing improved survival and time before growth, and more tumors vanished at surgery. Response and disease control rates rose. Survival gains held across all cancer types and both drug classes. One class, aimed at PD-1, beat the other on time before growth. Repeat checks confirmed stability. The authors back broad use of the pairing, with PD-1 favored for delaying growth.
Catalog record
| CREATOR | Xiao Li, Yaqiong Song, Jianhua Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50877 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |